BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 18724199)

  • 21. X-Linked Hypophosphatemic Rickets: Multisystemic Disorder in Children Requiring Multidisciplinary Management.
    Baroncelli GI; Mora S
    Front Endocrinol (Lausanne); 2021; 12():688309. PubMed ID: 34421819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Young XLH Patients-Reported Experience with a Supportive Care Program.
    Rothenbuhler A; Gueorguieva I; Lichtenberger-Geslin L; Audrain C; Soskin S; Bensignor C; Rossignol S; Bertholet-Thomas A; Naudeau L; Bacchetta J; Linglart A
    Patient Prefer Adherence; 2023; 17():1393-1405. PubMed ID: 37325587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Asia-Pacific Consensus Recommendations on X-Linked Hypophosphatemia: Diagnosis, Multidisciplinary Management, and Transition From Pediatric to Adult Care.
    Munns CF; Yoo HW; Jalaludin MY; Vasanwala R; Chandran M; Rhee Y; But WM; Kong AP; Su PH; Numbenjapon N; Namba N; Imanishi Y; Clifton-Bligh RJ; Luo X; Xia W
    JBMR Plus; 2023 Jun; 7(6):e10744. PubMed ID: 37283655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Craniosynostosis in Patients With X-Linked Hypophosphatemia: A Review.
    Munns CF; Maguire EP; Williams A; Wood S; Biggin A
    JBMR Plus; 2023 May; 7(5):e10728. PubMed ID: 37197318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What are the benefits of the anti-FGF23 antibody burosumab on the manifestations of X-linked hypophosphatemia in adults in comparison with conventional therapy? A review.
    Lafage-Proust MH
    Ther Adv Rare Dis; 2022; 3():26330040221074702. PubMed ID: 37180412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Approach to Hypophosphatemic Rickets.
    Ackah SA; Imel EA
    J Clin Endocrinol Metab; 2022 Dec; 108(1):209-220. PubMed ID: 35981346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia.
    Trombetti A; Al-Daghri N; Brandi ML; Cannata-Andía JB; Cavalier E; Chandran M; Chaussain C; Cipullo L; Cooper C; Haffner D; Harvengt P; Harvey NC; Javaid MK; Jiwa F; Kanis JA; Laslop A; Laurent MR; Linglart A; Marques A; Mindler GT; Minisola S; Yerro MCP; Rosa MM; Seefried L; Vlaskovska M; Zanchetta MB; Rizzoli R
    Nat Rev Endocrinol; 2022 Jun; 18(6):366-384. PubMed ID: 35484227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical practice guidelines for paediatric X-linked hypophosphataemia in the era of burosumab.
    Sandy JL; Simm PJ; Biggin A; Rodda CP; Wall CL; Siafarikas A; Munns CF
    J Paediatr Child Health; 2022 May; 58(5):762-768. PubMed ID: 35426466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium.
    Laurent MR; De Schepper J; Trouet D; Godefroid N; Boros E; Heinrichs C; Bravenboer B; Velkeniers B; Lammens J; Harvengt P; Cavalier E; Kaux JF; Lombet J; De Waele K; Verroken C; van Hoeck K; Mortier GR; Levtchenko E; Vande Walle J
    Front Endocrinol (Lausanne); 2021; 12():641543. PubMed ID: 33815294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnosis and management of X-linked hypophosphatemia in children and adolescent in the Gulf Cooperation Council countries.
    Al Juraibah F; Al Amiri E; Al Dubayee M; Al Jubeh J; Al Kandari H; Al Sagheir A; Al Shaikh A; Beshyah SA; Deeb A; Habeb A; Mustafa M; Zidan H; Mughal MZ
    Arch Osteoporos; 2021 Mar; 16(1):52. PubMed ID: 33660084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment.
    Fukumoto S
    J Mol Endocrinol; 2021 Feb; 66(2):R57-R65. PubMed ID: 33295878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. X-Linked Hypophosphatemia: A New Era in Management.
    Dahir K; Roberts MS; Krolczyk S; Simmons JH
    J Endocr Soc; 2020 Dec; 4(12):bvaa151. PubMed ID: 33204932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X-Linked Hypophosphatemia: A Phase 3, Single-Arm, International Trial.
    Insogna KL; Rauch F; Kamenický P; Ito N; Kubota T; Nakamura A; Zhang L; Mealiffe M; San Martin J; Portale AA
    J Bone Miner Res; 2019 Dec; 34(12):2183-2191. PubMed ID: 31369697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. X-linked hypophosphatemic rickets: an Italian experts' opinion survey.
    Emma F; Cappa M; Antoniazzi F; Bianchi ML; Chiodini I; Eller Vainicher C; Di Iorgi N; Maghnie M; Cassio A; Balsamo A; Baronio F; de Sanctis L; Tessaris D; Baroncelli GI; Mora S; Brandi ML; Weber G; D'Ausilio A; Lanati EP
    Ital J Pediatr; 2019 May; 45(1):67. PubMed ID: 31151476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial.
    Imel EA; Glorieux FH; Whyte MP; Munns CF; Ward LM; Nilsson O; Simmons JH; Padidela R; Namba N; Cheong HI; Pitukcheewanont P; Sochett E; Högler W; Muroya K; Tanaka H; Gottesman GS; Biggin A; Perwad F; Mao M; Chen CY; Skrinar A; San Martin J; Portale AA
    Lancet; 2019 Jun; 393(10189):2416-2427. PubMed ID: 31104833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia.
    Haffner D; Emma F; Eastwood DM; Duplan MB; Bacchetta J; Schnabel D; Wicart P; Bockenhauer D; Santos F; Levtchenko E; Harvengt P; Kirchhoff M; Di Rocco F; Chaussain C; Brandi ML; Savendahl L; Briot K; Kamenicky P; Rejnmark L; Linglart A
    Nat Rev Nephrol; 2019 Jul; 15(7):435-455. PubMed ID: 31068690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosis, treatment-monitoring and follow-up of children and adolescents with X-linked hypophosphatemia (XLH).
    Rothenbuhler A; Schnabel D; Högler W; Linglart A
    Metabolism; 2020 Feb; 103S():153892. PubMed ID: 30928313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.
    Insogna KL; Briot K; Imel EA; Kamenický P; Ruppe MD; Portale AA; Weber T; Pitukcheewanont P; Cheong HI; Jan de Beur S; Imanishi Y; Ito N; Lachmann RH; Tanaka H; Perwad F; Zhang L; Chen CY; Theodore-Oklota C; Mealiffe M; San Martin J; Carpenter TO;
    J Bone Miner Res; 2018 Aug; 33(8):1383-1393. PubMed ID: 29947083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The orthopaedic management of lower limb deformity in hypophosphataemic rickets.
    Horn A; Wright J; Bockenhauer D; Van't Hoff W; Eastwood DM
    J Child Orthop; 2017 Aug; 11(4):298-305. PubMed ID: 28904636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conventional Therapy in Adults With XLH Improves Dental Manifestations, But Not Enthesopathy.
    Econs MJ
    J Clin Endocrinol Metab; 2015 Oct; 100(10):3622-4. PubMed ID: 26439151
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.